During Q2 2018 the big money sentiment decreased to 1.34. That’s change of 0.59, from 2018Q1’s 1.93. 11 investors sold all, 21 reduced holdings as PACB ratio fall. 33 increased stakes while 10 funds bought stakes. Funds hold 85.41 million shares thus 3.21% less from 2018Q1’s 88.24 million shares. The Germany-based Deutsche State Bank Ag has invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Lpl Fincl Limited invested in 0% or 20,690 shs. 159,318 are held by Goldman Sachs Grp. Prudential stated it has 10,612 shs. Proshare Advsr Limited Liability Com holds 71,466 shs. California Public Employees Retirement System holds 0% of its capital in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 457,400 shs. 191,246 are owned by Swiss National Bank. Financial Bank Of America Corp De invested in 0% or 16,557 shs. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its capital in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Great West Life Assurance Co Can reported 9,087 shs. Voya Invest Mngmt Ltd Liability Corp, a Georgia-based fund reported 46,997 shs. 71,888 were reported by One Trading Lp. D E Shaw Inc holds 0% of its capital in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 11,613 shs. Legal General Public Ltd Liability Co has 17,990 shs. 2,115 were accumulated by Piedmont Advsr Ltd Liability Company.
The stake In Pacific Biosciences Calif In (PACB) was reduced owned by Blackstone Group Lp. According to 2018Q2 SEC form the reduction is 41.52%. By selling 1.71 million shares Blackstone Group Lp made the stock popped up with 47.72%. The institutional investor is holding 2.41M shares, compared to the 4.12 million from the previous quarter. And the announced value of the capital goods company is $8.56M for the 2018Q2. $1.13 billion is the MC of Pacific Biosciences Calif In. Ticker’s shares touched $7.74 during the last trading session after 0.77% change.Pacific Biosciences of California, Inc. has 3.84M shares volume, 14.50% up from normal. PACB is downtrending and has moved 10.66% since November 10, 2017. PACB underperformed the S&P500 by 26.28%.
For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .
For more Pacific Biosciences of California, Inc. (NASDAQ:PACB) news published recently go to: Streetinsider.com, Benzinga.com, Nasdaq.com, Fool.com or Globenewswire.com. The titles are as follows: “Pre-Open Movers 11/02: (PACB) (ANET) (CZR) Higher; (PBYI) (OLED) (MDRX) (AAPL) Lower (more…)” published on November 02, 2018, “Illumina Buys Rival Pacific Biosciences In $1.2B Deal” on November 02, 2018, “Why Alkermes’ Depression Drug Stumbled, and How Illumina Plans to Profit From M&A” with a publish date: November 08, 2018, “Here’s Why Illimuna Just Bought Its Biggest Competitor” and the last “PacBio Long-Read Sequencing Featured at ASHG Annual Meeting” with publication date: October 15, 2018.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Ratings Coverage
In total 2 analysts cover Pacific Biosciences (NASDAQ:PACB). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:PACB)’s analyst reports since August 9, 2018 according to StockzIntelligence Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.